首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.
【24h】

A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.

机译:如果可行,T3,N1,M0或T1-3,N2,M0期非小细胞肺癌患者的术前化疗随机对照试验(如果可行)是切除与放疗。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The majority of patients with stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer are considered inoperable, and receive radical radiotherapy. This randomised trial aimed to assess whether, in this group of inoperable patients, a policy of neo-adjuvant chemotherapy (with mitomycin, ifosfamide and cisplatin (MIC) or mitomycin, vinblastine and cisplatin (MVP)) followed, if feasible, by surgery (CT-S), would result in better outcomes than radical radiotherapy (RT). The trial closed due to poor accrual, with only 48 patients randomised in 3 years. Only 4 of the 24 patients in the CT-S group had a complete resection, and of these, the 2 patients who had a pneumonectomy both died 12 days after surgery. There was no evidence of an improved survival in the CT-S group (median survival 13.8 months, compared with 11.3 months for the RT group), but because the trial failed to recruit we were unable to reach any reliable conclusions about these two treatment options.
机译:大多数患有T3,N1,M0或T1-3,N2,M0非小细胞肺癌的患者被认为无法手术,并接受了放射治疗。这项随机试验旨在评估在这组无法手术的患者中,如果可行的话,是否采取新辅助化疗(丝裂霉素,异环磷酰胺和顺铂(MIC)或丝裂霉素,长春碱和顺铂(MVP))的政策( (CT-S)比根治性放疗(RT)产生更好的结果。由于预料不良,该试验结束了,只有48名患者在3年内被随机分组​​。 CT-S组的24例患者中只有4例完全切除,其中2例接受了肺切除术的患者均在手术后12天死亡。没有证据表明CT-S组的生存率有所改善(中位生存期为13.8个月,而RT组为11.3个月),但是由于该试验未能招募,因此我们无法就这两种治疗方案得出任何可靠的结论。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号